Introduction: Triple-negative breast cancer (TNBC) is associated with poor prognosis and
limited treatment options. However, TNBC is known to be more immunogenic compared to …

Introduction Triple-negative breast cancer (TNBC) accounts for approximately 10%-15% of
all diagnosed breast cancers and is associated with an aggressive natural history and poor …

Triple-negative breast cancer (TNBC) is defined by a lack of expression of both estrogen
(ER) and progesterone (PgR) receptors as well as human epidermal growth factor receptor …

Background Triple negative breast cancer (TNBC) is clinically aggressive breast cancer with
a poor prognosis. Approximately 20% of TNBC has been found to express programmed …

Importance Atezolizumab (anti–programmed cell death ligand 1 [PD-L1]) is well tolerated
and clinically active in multiple cancer types. Its safety and clinical activity in metastatic triple …

Atezolizumab (Tecentriq®), an immune checkpoint inhibitor against programmed death
ligand 1 (PD-L1), is the first immunotherapy agent to be approved (for use in combination …

Immunotherapy has become a mainstay of cancer treatment in many malignancies, though
its application in breast cancer remains limited. Of the breast cancer subtypes, triple …

Immune checkpoint inhibitors have shown efficacy against metastatic triple-negative breast
cancer (mTNBC) but only for PD-L1positive disease. The randomized, placebo-controlled …

Breast cancer is the most commonly diagnosed cancer (estimated 2.3 million new cases in
2020) and the leading cause of cancer death (estimated 685,000 deaths in 2020) in women …

Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype with
limited treatment options. Recently, there has been a growing interest in immunotherapy …